TuisALTME • EPA
add
TME Pharma NV
Vorige sluiting
€0,15
Dagwisseling
€0,14 - €0,15
Jaarwisseling
€0,11 - €0,44
Markkapitalisasie
6,40 m EUR
Gemiddelde volume
636,41 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
EPA
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (EUR) | Jun. 2024info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 1,37 m | -0,51% |
Netto inkomste | -1,62 m | 11,23% |
Netto winsgrens | — | — |
Wins per aandeel | — | — |
EBITDA | -1,34 m | 0,07% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (EUR) | Jun. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 2,70 m | -10,14% |
Totale bates | 2,94 m | -15,02% |
Totale aanspreeklikheid | 1,38 m | -62,07% |
Totale ekwiteit | 1,57 m | — |
Uitstaande aandele | 42,12 m | — |
Prys om te bespreek | 3,68 | — |
Opbrengs op bates | -116,29% | — |
Opbrengs op kapitaal | -217,64% | — |
Kontantvloei
Netto kontantverandering
| (EUR) | Jun. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -1,62 m | 11,23% |
Kontant van bedrywe | -1,37 m | 19,42% |
Kontant van beleggings | -4,00 k | 57,89% |
Kontant van finansiering | 1,60 m | 78,88% |
Netto kontantverandering | 229,00 k | 128,17% |
Beskikbare kontantvloei | -723,12 k | 3,18% |
Meer oor
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller.
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes. Wikipedia
Gestig
1997
Webwerf
Werknemers
13
